Bernstein Initiates Coverage of Roivant Sciences Ltd. (ROIV) with an Outperform Rating

On March 19, 2026, Bernstein initiated sum of Roivant Sciences Ltd. (NASDAQ:ROIV) with an Outperform standing and a $35 terms target, citing imaginable upside from upcoming objective readouts successful pulmonary hypertension associated with interstitial lung illness and non-infectious uveitis. The steadfast noted risks astir competitory information and motorboat execution, but said these concerns look “appropriately discounted.”

Earlier successful March, JPMorgan raised its terms people connected Roivant Sciences Ltd. (NASDAQ:ROIV) to $33 from $31 antecedently and maintained an Overweight standing aft updating its exemplary to bespeak the company’s colony with Moderna. JPMorgan described the statement arsenic a “major overhang lift,” shifting capitalist absorption toward upcoming objective catalysts.

H.C. Wainwright besides raised its terms people connected Roivant Sciences Ltd. (NASDAQ:ROIV) to $34 from $33 antecedently and reiterated a Buy rating, incorporating $2.25B successful litigation proceeds tied to a planetary colony betwixt Roivant subsidiary Genevant Sciences, Arbutus Biopharma, and Moderna related to lipid nanoparticle transportation technology.

Roivant Sciences Ltd. (NASDAQ:ROIV) develops and commercializes biopharmaceutical products crossed aggregate therapeutic areas.

While we admit the imaginable of ROIV arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years.

Disclosure: None. Follow Insider Monkey connected Google News.